Furthermore, recent studies also suggest a potential synergistic activity when ARS-853 is combined with receptor TKIs such as EGFR TKIs, indicating that covalent G12C-specific inhibitors might indeed be promising therapeutic agents used for the treatment of KRAS G12C-mutant NSCLC patients [103, 104, 108, 109]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.